Evaluation of dosing and clinical response to darbepoetin alfa (DA) and epoetin alfa (EPO) in patients treated for chemotherapy-induced anemia in hospital oncology outpatient clinics.

被引：0
作者：
Gupta, V
Rago, MA
Goetz, A
Fastenau, J
Watson, S
机构：
[1] Cardinal Hlth Clin Serv & Consulting, Pharmaceut & Clin Informat Serv, Houston, TX USA
[2] Ortho Biotech, Clin Affairs, Bridgewater, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5768
引用
收藏
页码：509B / 509B
页数：1
相关论文
共 50 条
  • [21] Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies
    Case, Ashley S.
    Rocconi, Rodney P.
    Kilgore, Larry C.
    Barnes, Mack N.
    GYNECOLOGIC ONCOLOGY, 2006, 101 (03) : 499 - 502
  • [22] COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN A CHRONIC KIDNEY DISEASE POPULATION TREATED IN THE HOSPITAL OUTPATIENT SETTING
    Vekeman, Francis
    McKenzie, R. Scott
    Lafeuille, Marie-Helene
    Bailey, Robert A.
    Piech, Catherine Tak
    Lefebvre, Patrick
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) : A78 - A78
  • [23] CHEMOTHERAPY-INDUCED ANEMIA MANAGEMENT WITH DARBEPOETIN ALFA IN DAILY CLINICAL PRACTICE
    Cruz, M. A.
    Bustos, A.
    Carabantes, F.
    Diaz, N.
    Rovira, P. Sanchez
    Froilan, J.
    Lorenzo, I.
    Gasquet, J. A.
    Alegre, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 284 - 284
  • [24] Darbepoetin alfa for the treatment of chemotherapy-induced anemia in patients with solid tumors
    Bustos, A.
    Carabantes, F.
    Alvarez, R.
    Diaz, N.
    Bueso, P.
    Lazaro, M.
    Gasquet, J. A.
    Alegre, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 197 - 197
  • [25] Evaluation of extended dosing intervals versus weekly dosing of darbepoetin alfa (DA): A phase 2 study in cancer patients (pts) with chemotherapy-induced anemia (CIA)
    Rearden, T.
    Schwartzberg, L.
    Mirtsching, B.
    Tomita, D.
    Lillie, T.
    Burkes, R.
    Silberstein, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 154 - 154
  • [26] COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN A CHRONIC KIDNEY DISEASE POPULATION TREATED IN THE HOSPITAL INPATIENT AND OUTPATIENT SETTING
    Lafeuille, Marie-Helene
    Bailey, Robert A.
    Senbetta, Mekre
    Lefebvre, Patrick
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (04) : A56 - A56
  • [27] Anemia Management With Darbepoetin-Alfa in Outpatient Hemodialysis Patients Switched From Epoetin-Alfa: A Community Hospital Experience
    Agrawal, Varun
    Mukherjee, Sudipto
    Kosuri, Rajani
    Dumler, Francis
    AMERICAN JOURNAL OF THERAPEUTICS, 2010, 17 (05) : 469 - 475
  • [28] ARTIST: Evaluation of the current management of hemoglobin (Hb) levels in cancer patients with symptomatic chemotherapy-induced anemia (CIA) treated with darbepoetin alfa (DA)
    Smakal, M.
    Ruzsa, A.
    Hemetsberger, M.
    Kurhanska, A.
    Ianakieva, V.
    Niepel, D.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S51 - S52
  • [29] Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: A retrospective cohort study
    Nurko, Saul
    Spirko, Rita
    Law, Amy
    Dennis, Vincent W.
    CLINICAL THERAPEUTICS, 2007, 29 (09) : 2010 - 2021
  • [30] Hematologic outcomes and costs in epoetin alfa (EPO) and darbepoetin alfa (DARB) treated cancer patients with anemia: results of the Dosing and Outcomes Study of Erythropoiesis Stimulating Therapies (DOSE Registry).
    Memisoglu, A
    Peake, C
    Vichare, R
    McKenzie, RS
    Howell, J
    Piech, CT
    PHARMACOTHERAPY, 2005, 25 (10): : 1469 - 1469
12345